From the Research
Relationship between Subdural Hematoma and Brilinta (Ticagrelor)
- The use of antiplatelet agents, such as ticagrelor (Brilinta), has been associated with an increased risk of intracranial hemorrhage, including subdural hematoma 1.
- A case report described a patient who developed a spontaneous acute subdural hematoma while on antiplatelet therapy with aspirin and ticagrelor, highlighting the potential risk of intracranial bleeding with these medications 1.
- Another case report described a patient with end-stage renal disease who developed an acute spontaneous subdural hematoma after starting dual antiplatelet therapy with aspirin and ticagrelor post drug-eluting stent insertion 2.
- The risk of intracranial hemorrhage, including subdural hematoma, may be higher in patients receiving aspirin with ticagrelor, especially in those with reduced estimated glomerular filtration rate (eGFR) and liver disease 2.
- The management of subdural hematomas involves medical and surgical interventions, and the use of antiplatelet agents may need to be reversed or discontinued in patients with subdural hematomas 3, 4.
- The natural history of acute subdural hematomas can be affected by various factors, including age, anticoagulant use, and underlying brain injury, but the use of antiplatelet agents like ticagrelor may also play a role 4.